MedTrace Logo

A Phase II Trial of CyberKnife Radiosurgery to Perioptic Tumors

NCT02225197 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-07-25

No results posted yet for this study

Summary

The purpose of this study is to find out what effects (good and bad) CyberKnife stereotactic radiosurgery has on tumors near the critical structures of the eye (optic apparatus).

The investigators hypothesize that hypofractionated stereotactic radiotherapy via the CyberKnife ® can deliver tumor ablating doses of radiation to perioptic lesions safely and effectively while sparing the adjacent optic apparatus and normal brain tissues from receiving damaging doses of radiation.

Conditions

  • Tumor, Benign, Optic Nerve

Interventions

RADIATION

CyberKnife Radiosurgery

25 Gy delivered in 5 fractions of 5 Gy per fraction

Sponsors & Collaborators

  • Community Cancer Center, Normal, Illinois

    lead OTHER

Principal Investigators

  • Shermian Woodhouse, MD · Community Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2017-10-31
Completion
2017-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02225197 on ClinicalTrials.gov